Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib for Bone Marrow Protection in Advanced Bile Duct and Pancreatic Cancer
NCT07160283Phase 2Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Shandong First Medical University
- Start
- Sep 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of trilaciclib in chemotherapy-induced neutropenia (CIN), sponsored by Second Affiliated Hospital of Shandong First Medical University. Primary endpoint: Incidence of Grade >=3 Chemotherapy-Induced Neutropenia. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
trilaciclib
03
Conditions
chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on NCT07160283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07160283.